Novo Nordisk AI Stock Analysis
Want to see NVO full AI Analyst Report?
Novo Nordisk (NVO) AI Stock Analysis
Novo Nordisk
(NYSE:NVO)
The score is driven primarily by strong financial performance (exceptional profitability and growth with a solid balance sheet) and attractive valuation (low P/E and high dividend yield). Offsetting these positives are weaker cash-flow conversion, mixed longer-term technical trend despite improved short-term momentum, and earnings-call risks centered on near-flat 2026 guidance with ongoing pricing pressure, loss-of-exclusivity impacts, and China headwinds.
Novo Nordisk Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where Novo Nordisk is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Novo Nordisk’s growth is shifting from a North America–dominated surge to a more balanced, global footprint: North America shows sharp quarter-to-quarter volatility (notably a late‑2024 peak and subsequent normalization), while International revenue has climbed steadily and accelerated into 2025–mid‑2026. That suggests adoption and reimbursement gains outside the U.S. are de‑risking the company’s revenue mix, but investors should watch continued U.S. channel/pricing swings and emerging competition that could reintroduce short‑term volatility.
The FlyNovo Nordisk (NVO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $183.34B
- Dividend Yield
- 4.37%
- Average Volume (3M)
- 12.24M
- Price to Earnings (P/E)
- 10.7
- Beta (1Y)
- 1.15
- Revenue Growth
- 11.16%
- EPS Growth
- 15.62%
- Country
- US
- Employees
- 68,794
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
Novo Nordisk Business Overview & Revenue Model
Company Description
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Af...
How the Company Makes Money
Novo Nordisk makes money primarily by selling branded prescription medicines and related drug-delivery devices to healthcare systems and channel partners worldwide. Its core revenue model is volume-and-price driven sales of patented pharmaceuticals,...
Novo Nordisk Earnings Call Summary
The call was broadly positive, supported by Q3 sales and operating profit growth, improving patient volumes, strong uptake of the Wegovy and Ozempic pills, substantial clinical and pipeline progress, an accelerated international rollout, and raised 2026 guidance. However, management also highlighted near-flat full-year guidance, U.S. and international pricing pressure, loss-of-exclusivity impacts, China headwinds, payer resistance, and normalization of early Wegovy pill uptake. Highlights significantly outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Novo’s 2030 ambition is to deliver mid-single-digit compounded annual sales growth in line with our industry peers from 2026 to 2030; for 2026, adjusted sales growth is now expected to be -2% to +2% at CER, adjusted operating profit growth is now expected to be from - 2% to + 2% at constant exchange rates, and free cash flow is now expected between DKK 60 billion and DKK 70 billion. By first half of 2027, Wegovy pill is expected to be available in more than 20 markets; Frehemgo is planned to roll out globally during 2027, pending approval; denecimig is expected to launch in European countries by the turn of this year, with a broader rollout in 2027, and in the U.S. in the first half of 2027, pending regulatory decision. AMAZE 9 is expected to read out in 2028, Amylin 355 is expected to read out in the second half of 2027 in around 170 patients, ACSL5 inhibitor phase I results are anticipated in the second half of 2027, RENEW 1 and 2 phase III results are anticipated around mid-2027, and phase I/II results for both tri-agonists are anticipated in the first half of 2027.
Novo Nordisk Financial Statement Overview
Summary
Overall fundamentals are strong, led by exceptional income-statement strength (very high margins and strong TTM growth) and a solid balance sheet with high ROE and manageable leverage. The key offset is weaker cash-flow conversion and slightly declining free cash flow versus earnings, which reduces quality-of-earnings and financial flexibility if growth normalizes.
Income Statement
93Very PositiveBalance Sheet
84Very PositiveCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 333.65B | 309.06B | 290.40B | 232.26B | 176.95B | 140.80B |
| Gross Profit | 269.57B | 250.28B | 245.88B | 196.50B | 148.51B | 117.14B |
| EBITDA | 184.57B | 156.73B | 147.94B | 114.63B | 76.80B | 65.39B |
| Net Income | 113.18B | 102.43B | 100.99B | 83.68B | 55.52B | 47.76B |
Balance Sheet | ||||||
| Total Assets | 599.16B | 542.90B | 465.80B | 314.49B | 241.26B | 194.51B |
| Cash, Cash Equivalents and Short-Term Investments | 49.18B | 26.96B | 26.31B | 30.23B | 23.57B | 17.48B |
| Total Debt | 134.48B | 130.96B | 102.79B | 27.01B | 25.78B | 26.64B |
| Total Liabilities | 381.36B | 348.86B | 322.31B | 207.93B | 157.77B | 123.76B |
| Stockholders Equity | 217.80B | 194.05B | 143.49B | 106.56B | 83.49B | 70.75B |
Cash Flow | ||||||
| Free Cash Flow | 46.32B | 28.99B | 69.66B | 70.01B | 64.13B | 47.62B |
| Operating Cash Flow | 128.15B | 119.10B | 120.97B | 108.91B | 78.89B | 55.00B |
| Investing Cash Flow | -82.60B | -79.16B | -128.90B | -43.89B | -24.92B | -31.61B |
| Financing Cash Flow | -33.54B | -28.41B | 8.73B | -63.16B | -51.80B | -25.49B |
Novo Nordisk Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVO, the sentiment is Positive. The current price of 41.09 is above the 20-day moving average (MA) of 39.76, above the 50-day MA of 40.33, and below the 200-day MA of 42.88, indicating a neutral trend. The MACD of 0.32 indicates Negative momentum. The RSI at 55.90 is Neutral, neither overbought nor oversold. The STOCH value of 50.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVO.
Novo Nordisk Risk Analysis
Novo Nordisk disclosed 17 risk factors in its most recent earnings report. Novo Nordisk reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskNovo Nordisk Peers Comparison
Overall Rating
SNY83Outperform
LLY81Outperform- NVO80Outperform
AMGN75Outperform
NVS72Outperform
MRK64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SNY | 83Outperform | $114.40B | 24.82 | 5.84% | 4.99% | 23.68% | -30.90% |
| LLY | 81Outperform | $1.35T | 46.54 | 83.65% | 0.46% | 45.51% | 50.48% |
| NVO | 80Outperform | $178.67B | 10.69 | 54.14% | 4.37% | 11.16% | 15.62% |
| AMGN | 75Outperform | $251.65B | 26.93 | 85.59% | 2.12% | 8.60% | 33.48% |
| NVS | 72Outperform | $295.79B | 30.66 | 24.24% | 2.96% | 1.64% | -28.72% |
| MRK | 64Neutral | $364.98B | 150.19 | 5.29% | 2.31% | 5.21% | -86.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NVO | Novo Nordisk | 41.09 | -5.58 | -11.96% | |
| AMGN | Amgen Inc | 468.11 | 140.46 | 42.87% | |
| LLY | Eli Lilly And Company | 1437.29 | 416.94 | 40.86% | |
| MRK | Merck & Company | 147.18 | 56.91 | 63.05% | |
| NVS | Novartis AG | 160.32 | 31.58 | 24.53% | |
| SNY | Sanofi SA | 48.43 | -1.71 | -3.41% |
Novo Nordisk Corporate Events
Novo Nordisk Raises 2026 Outlook on Q3 GLP-1 Momentum
Novo Nordisk, a pharmaceutical company focused on diabetes, obesity and other chronic diseases, markets GLP-1 medicines including Wegovy®, Ozempic® and Rybelsus®. Its commercial strategy has centered on expanding obesity treatments across the United...
Novo Nordisk Buys DKK 377 Million of Shares in Latest Repurchase Round
Novo Nordisk is a global healthcare company that develops medicines and support programs for chronic diseases, with a major focus on diabetes and obesity. The Denmark-based company employs more than 67,000 people and markets its B shares in Copenhage...
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
On 26 October 2026, Novo Nordisk reported progress in a major share repurchase programme that forms part of a broader DKK 15 billion buyback running over 12 months from 4 February 2026. Initiated on 6 May 2026 under EU Safe Harbour rules, the current...
Novo Nordisk Expands 2026 Share Buyback, Lifting Treasury Stake to 1.2%
Novo Nordisk has been carrying out a substantial share repurchase programme during 2026 under EU Market Abuse Regulation safe harbour rules, reinforcing capital management and signalling confidence in its long‑term prospects. The initiative is part o...
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
On 12 October 2026, Novo Nordisk reported progress under its ongoing share repurchase programme, which forms part of a broader plan to buy back up to DKK 15 billion of B shares over the 12-month period starting 4 February 2026. The company has been e...
Novo Nordisk Expands Treasury Stake as DKK 15bn Buyback Nears DKK 10bn Mark
Novo Nordisk has continued executing its DKK 15 billion, 12‑month share repurchase programme launched on 4 February 2026, with a sub-programme begun on 6 May 2026 to buy back up to about DKK 11.2 billion of B shares through 1 February 2027. Between 2...
Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme
On 28 September 2026, Novo Nordisk reported progress on its ongoing share repurchase programme, part of a broader capital return plan of up to DKK 15 billion over the 12-month period that began on 4 February 2026. Initiated on 6 May 2026 under the EU...
Novo Nordisk Details Progress on DKK 15 Billion Share Buyback Programme
Novo Nordisk A/S, the Danish healthcare group specialising in treatments for serious chronic diseases with a heritage in diabetes, operates in about 170 countries and employs roughly 68,800 people. Its B shares trade on Nasdaq Copenhagen and its Amer...
Novo Nordisk Wins EMA Panel Backing for New Haemophilia A Therapy FREHEMGO
Novo Nordisk announced on 17 September 2026 that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending EU marketing authorisation for FREHEMGO (denecimig) to treat haemophilia A in a...
Novo Nordisk Nears DKK 9.3 Billion in Share Buybacks Under 2026 Programme
Novo Nordisk has been executing a substantial share repurchase programme as part of its capital-allocation strategy, targeting up to DKK 15 billion in B-share buybacks over a 12‑month period that began on 4 February 2026. The programme, conducted und...
Novo Nordisk Advances DKK 15 Billion Share Buyback, Holding 1% of Capital in Treasury Stock
Novo Nordisk has continued executing its previously announced share repurchase programme, which forms part of a broader plan to buy back up to DKK 15 billion of B shares over the 12-month period beginning 4 February 2026. Between 31 August and 4 Sept...
Novo Nordisk Advances DKK 15 Billion Share Buyback Programme Through Late August 2026
Novo Nordisk, a Danish healthcare company specialising in treatments for serious chronic diseases such as diabetes, operates globally with a workforce of about 68,800 and a commercial footprint in around 170 countries. Its B shares trade on Nasdaq Co...
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
On 6 May 2026, Novo Nordisk launched a share repurchase programme under EU Safe Harbour rules as part of a broader plan to buy back up to DKK 15 billion of B shares over a 12‑month period starting 4 February 2026. Under this specific programme, the c...
Novo Nordisk Expands Treasury Stock as 2026 Share Buyback Passes DKK 8 Billion
On 6 May 2026, Novo Nordisk launched a share repurchase programme under EU Safe Harbour rules as part of a broader plan to buy back up to DKK 15 billion of B shares over the 12 months starting 4 February 2026. Under the specific programme running fro...
Novo Nordisk Expands Treasury Position as 2026 Share Buyback Nears DKK 8 Billion
Novo Nordisk reported on August 10, 2026 the latest progress in its ongoing share repurchase programme, part of a broader plan to buy back up to DKK 15 billion of B shares over the 12‑month period starting February 4, 2026. Under the sub‑programme la...
Novo Nordisk reports vesting of 100th Anniversary restricted shares to board and EVP
On 6 August 2026, Novo Nordisk disclosed a series of insider transactions involving board members and a senior executive, reported under EU market abuse rules. The filings show that several directors and Executive Vice President for International Ope...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026